Patents by Inventor Karrie Ka Wai Wong

Karrie Ka Wai Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY
    Publication number: 20220143084
    Abstract: The present disclosure is directed to the generation of NK cells (or other lymphocytes) from induced pluripotent cells that have been derived from cells, e.g., developmentally mature T cells, and uses thereof for immunotherapy.
    Type: Application
    Filed: February 14, 2020
    Publication date: May 12, 2022
    Applicant: Editas Medicine, Inc.
    Inventors: Gordon Grant Welstead, Christopher Borges, Karrie Ka Wai Wong
  • Assay for Soluble CD200
    Publication number: 20120264145
    Abstract: The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200.
    Type: Application
    Filed: May 18, 2012
    Publication date: October 18, 2012
    Applicant: TRILLIUM THERAPEUTICS INC.
    Inventors: Reginald M. Gorczynski, Karrie Ka Wai Wong
  • Assay for soluble CD200
    Patent number: 8206897
    Abstract: The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: June 26, 2012
    Assignee: Trillium Therapeutics Inc.
    Inventors: Reginald M. Gorczynski, Karrie Ka Wai Wong
  • ASSAY FOR SOLUBLE CD200
    Publication number: 20110052605
    Abstract: The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200.
    Type: Application
    Filed: July 29, 2008
    Publication date: March 3, 2011
    Inventors: Reginald M. Gorczynski, Karrie Ka, Wai Wong